Korean J Psychopharmacol.
2006 Mar;17(2):203-211.
The Effectiveness of 6-month Treatment with Citalopram in Korean Panic Disorder Patients: A Prospective, Open-labeled, Multi-Center Trial
- Affiliations
-
- 1Youngkwang Christian Sin Ha Hospital, Youngkwang, Korea.
- 2Department of Psychiatry, Chonnam National University Hospital, Kwangju, Korea.
- 3Mettaa Institute of Cognitive Behavior Therapy, Seoul, Korea.
- 4Department of Psychiatry, Keimyung University School of Medicine, Taegu, Korea.
- 5Department of Psychiatry, WonKwang University School of Medicine, Iksan, Korea.
- 6Department of Psychiatry, Inje University College of Medicine, Ilsan Paik Hospital, Goyang, Korea.
- 7Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 8Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bhyu@smc.samsung.co.kr
Abstract
OBJECTIVE
The authors examined the efficacy of citalopram, and its effect on the quality of life in patients with panic disorder. METHOD: Seventy three patients who had panic disorder were recruited for this study. They did not have major depression and other axis I diseases. They were scheduled to be examined 4 times (at baseline, 4, 12 and 24 weeks) and took citalopram for 24 weeks with a flexible dosing schedule. The primary efficacy variables were the response and remission rates (response: HAMA total score decreased by at least 50% from baseline; remission: HAMA total score < or = 7). Other variables included the Hamilton Rating Scale for Depression, Panic Disorder Severity Scale (PDSS), Acute Panic Inventory, Clinical Global Impression Scale and Sheehan Disabilities Scale (SDS).
RESULTS
The number of patients who completed 24 weeks of treatment was 33 (45.2%). Forty patients who were dropped out consisted of 4 patients with symptom improvement and 36 patients with failure to return. Response/remission rates were 56.2/31.5% in the last-observation-carried-forward methods and 87.9/69.7% in the observed case data. Treatment with citalopram improved anxiety and depressive symptoms during 24 weeks on all efficacy measures. By a completed patient analysis, citalopram also significantly improved the disability scores on SDS. In this study, any serious adverse effects were not observed.
CONCLUSION
Treatment with citalopram was effective and well-tolerated for the patients with panic disorder, and also improved quality of life in the patients.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report
- Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial
- Sleep in Panic Disorder and Nocturnal Panic Attack
- Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018
- Clinical Characteristics of the Respiratory Subtype in Panic Disorder Patients
